Drug Trial Radar · NCT06838000
Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents
Last checked: Nov 20, 2026Latest source record: Oct 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,268
Actual
Start
Feb 28, 2025
Primary completion
Dec 1, 2026
Study completion Dec 1, 2026
Sponsor
- Lead sponsor
- Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Feb 20, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 7 months, up to 17 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and immunogenicity of PCV21 versus 20vPCV ( 20-valent pneumococcal conjugate vaccine, Prevnar 20) for catch-up vaccination in infants (7 to 11 MoA-Months of age), toddlers (12 to 23 MoA), and children/adolescents (2 to 5 YoA and 6 to 17 YoA-years of age).
Conditions
- Pneumococcal Infections
Interventions
PCV21Biological
Investigational pneumococcal conjugate vaccine
20vPCVBiological
20-valent pneumococcal conjugate vaccine
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants reporting immediate adverse events (AEs)Time frame: Within 30 minutes post-vaccination
- Number of participants reporting solicited injection site and solicited systemic reactionsTime frame: Up to Day 7 post-vaccination
- Number of participants reporting unsolicited (spontaneously reported) injection site reactions and unsolicited systemic AEs after each and any injection of a pneumococcal vaccineTime frame: Within 30 days after vaccination
- Number of participants reporting serious adverse events (SAEs) and adverse events of special interest (AESIs)Time frame: From day 0 to day 517
- Number of Infants (7-11 months of age [MoA]) and toddlers (12-23 MoA): with serotype-specific IgG concentrations for all serotypes included in PCV21Time frame: On day 30 after last vaccination
- Number of Children (2-5 years of age [YoA]):with serotype specific OPA titers for all serotypes included in PCV21Time frame: On day 30
- Number of Children (2-5 years of age [YoA]):with serotype specific IgG concentrations for all serotypes included in PCV21Time frame: On day 30
- Number of Children/adolescents (6-17 YoA):with serotype specific OPA titers for all serotypes included in PCV21Time frame: On day 30
Locations
38 sites in 4 countries. Site status is shown where the registry gives one.
Site # 8400008
Paramount, California
Site # 8400024
Doral, Florida
Site # 8400007
Hialeah, Florida
Site # 8400014
Melbourne, Florida
Site # 8400009
Miami, Florida
Site # 8400016
Miami, Florida
Site # 8400021
Fayetteville, Georgia
Site # 8400004
Union City, Georgia
Site # 8400003
Sioux City, Iowa
Site # 8400023
Erlanger, Kentucky
Site # 8400018
Biloxi, Mississippi
Site # 8400012
Ridgeland, Mississippi
Site # 8400002
Omaha, Nebraska
Site #8400010
Binghamton, New York
Site # 8400025
Rochester, New York
Site # 8400001
Houston, Texas
Site # 8400017
Stephenville, Texas
Site # 2330004
Tartu, Estonia
Site # 2330006
Tallinn, Harju, Estonia
Site # 2330007
Tallinn, Harju, Estonia
Site # 2330002
Tallinn, Harju, Estonia
Site # 2330003
Tallinn, Harju, Estonia
Site # 2330001
Paide, Järvamaa, Estonia
Site # 2330005
Tartu, Tartu, Estonia
Site # 6160002
Bydgoszcz, Poland
Site # 6160004
Bydgoszcz, Poland
Site # 6160006
Kłodzko, Poland
Site # 6160001
Torun, Poland
Site # 6160009
Lodz, Lodskie, Poland
Site # 6160007
Warsaw, Masovian Voivodeship, Poland
Site # 6160003
Częstochowa, Silesian Voivodeship, Poland
Site # 7640008
Bangkok, Thailand
Site # 7640006
Bangkok, Thailand
Site # 7640007
Bangkok, Thailand
Site # 7640004
Chiang Mai, Thailand
Site # 7640001
Pathum Thani, Thailand
Site # 7640002
Hat Yai, Changwat Songkhla, Thailand
Site # 7640003
Mueang Nonthaburi, Chiang Mai, Thailand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.